WO2008090960A1 - ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物 - Google Patents
ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物 Download PDFInfo
- Publication number
- WO2008090960A1 WO2008090960A1 PCT/JP2008/050994 JP2008050994W WO2008090960A1 WO 2008090960 A1 WO2008090960 A1 WO 2008090960A1 JP 2008050994 W JP2008050994 W JP 2008050994W WO 2008090960 A1 WO2008090960 A1 WO 2008090960A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antibody composition
- genetically recombinant
- recombinant antibody
- ganglioside
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/524,215 US20110236374A1 (en) | 2007-01-24 | 2008-01-24 | Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2 |
JP2008555105A JPWO2008090960A1 (ja) | 2007-01-24 | 2008-01-24 | ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物 |
EP08703821A EP2107115A1 (en) | 2007-01-24 | 2008-01-24 | Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007013641 | 2007-01-24 | ||
JP2007-013641 | 2007-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008090960A1 true WO2008090960A1 (ja) | 2008-07-31 |
Family
ID=39644534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/050994 WO2008090960A1 (ja) | 2007-01-24 | 2008-01-24 | ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20110236374A1 (ja) |
EP (1) | EP2107115A1 (ja) |
JP (1) | JPWO2008090960A1 (ja) |
WO (1) | WO2008090960A1 (ja) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010018846A1 (ja) * | 2008-08-13 | 2010-02-18 | 協和発酵キリン株式会社 | ガングリオシドgm2に特異的に結合する抗体組成物を含む医薬 |
WO2011078332A1 (ja) * | 2009-12-25 | 2011-06-30 | 中外製薬株式会社 | ポリペプチド多量体を精製するためのポリペプチドの改変方法 |
WO2012073985A1 (ja) * | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9334331B2 (en) | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
US10253091B2 (en) | 2009-03-19 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11485790B2 (en) | 2014-04-07 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
US11505605B2 (en) | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
US11851476B2 (en) | 2011-10-31 | 2023-12-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
SG11201504106XA (en) | 2012-12-06 | 2015-07-30 | Univ Kanazawa Nat Univ Corp | Therapeutic method for mesothelioma |
DK2953634T3 (da) | 2013-02-07 | 2021-08-30 | Massachusetts Gen Hospital | Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler |
CN115043943A (zh) * | 2015-05-15 | 2022-09-13 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
KR102410778B1 (ko) | 2016-05-13 | 2022-06-21 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59140885A (ja) | 1983-01-13 | 1984-08-13 | マツクス・プランク・ゲゼルシヤフト・ツア・フエルデルング・デア・ヴイツセンシヤフテン・エ−・フアウ | 植物細胞ゲノムへの発現可能な遺伝子の導入法 |
JPS6070080A (ja) | 1983-02-24 | 1985-04-20 | レイクスニベルシテイト ライデン | 双子葉植物の染色体への外来性dνaの組込方法 |
JPS60251887A (ja) | 1984-05-11 | 1985-12-12 | ノバルティス アクチエンゲゼルシャフト | 植物のプロトプラストの形質転換法 |
JPS63299A (ja) | 1986-04-22 | 1988-01-05 | イミユネツクス・コ−ポレ−シヨン | ヒトg−csfタンパク質の発現 |
JPS63309192A (ja) | 1987-02-17 | 1988-12-16 | ファーミング ビーブイ | 効率的な分泌のための乳腺に出される蛋白におけるdna配列 |
EP0327378A1 (en) | 1988-02-05 | 1989-08-09 | The Trustees Of Columbia University In The City Of New York | Domain-modified constant region antibodies |
JPH02227075A (ja) | 1988-09-29 | 1990-09-10 | Kyowa Hakko Kogyo Co Ltd | 新規ポリペプチド |
JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
JPH04311385A (ja) | 1991-04-10 | 1992-11-04 | Kyowa Hakko Kogyo Co Ltd | ハイブリドーマの製造法 |
JPH05336963A (ja) | 1991-12-17 | 1993-12-21 | Kyowa Hakko Kogyo Co Ltd | 新規α2→3シアリルトランスフェラーゼ |
WO1994000977A1 (en) | 1992-07-07 | 1994-01-20 | Japan Tobacco Inc. | Method of transforming monocotyledon |
EP0598998A2 (en) | 1992-09-07 | 1994-06-01 | Kyowa Hakko Kogyo Co., Ltd | Humanized antibodies reacting with the ganglioside GM2 |
WO1994023021A1 (en) | 1993-03-29 | 1994-10-13 | Kyowa Hakko Kogyo Co., Ltd. | α-1,3-FUCOSYLTRANSFERASE |
JP2517813B2 (ja) | 1990-05-29 | 1996-07-24 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | 生きている細胞に生物学的物質を導入するための改良された方法および装置 |
WO1997010354A1 (en) | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR |
JP2606856B2 (ja) | 1986-12-05 | 1997-05-07 | アグラシータス | 生細胞中に遺伝物質担持担体粒子を注入するための装置 |
JPH10257893A (ja) | 1997-03-19 | 1998-09-29 | Kyowa Hakko Kogyo Co Ltd | ガングリオシドgm2に対するヒト型相補性決定領域(cdr)移植抗体 |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
US20030158389A1 (en) | 1998-04-02 | 2003-08-21 | Genentech, Inc. | Polypeptide variants |
WO2003085107A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellules à génome modifié |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20050054832A1 (en) | 2002-03-01 | 2005-03-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
WO2007011041A1 (ja) * | 2005-07-22 | 2007-01-25 | Kyowa Hakko Kogyo Co., Ltd. | 遺伝子組換え抗体組成物 |
WO2010055993A1 (ko) | 2008-11-11 | 2010-05-20 | 시스템디엔디(주) | 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법 |
-
2008
- 2008-01-24 JP JP2008555105A patent/JPWO2008090960A1/ja not_active Withdrawn
- 2008-01-24 EP EP08703821A patent/EP2107115A1/en not_active Withdrawn
- 2008-01-24 US US12/524,215 patent/US20110236374A1/en not_active Abandoned
- 2008-01-24 WO PCT/JP2008/050994 patent/WO2008090960A1/ja active Application Filing
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59140885A (ja) | 1983-01-13 | 1984-08-13 | マツクス・プランク・ゲゼルシヤフト・ツア・フエルデルング・デア・ヴイツセンシヤフテン・エ−・フアウ | 植物細胞ゲノムへの発現可能な遺伝子の導入法 |
JPS6070080A (ja) | 1983-02-24 | 1985-04-20 | レイクスニベルシテイト ライデン | 双子葉植物の染色体への外来性dνaの組込方法 |
JPS60251887A (ja) | 1984-05-11 | 1985-12-12 | ノバルティス アクチエンゲゼルシャフト | 植物のプロトプラストの形質転換法 |
JPS63299A (ja) | 1986-04-22 | 1988-01-05 | イミユネツクス・コ−ポレ−シヨン | ヒトg−csfタンパク質の発現 |
JP2606856B2 (ja) | 1986-12-05 | 1997-05-07 | アグラシータス | 生細胞中に遺伝物質担持担体粒子を注入するための装置 |
JPS63309192A (ja) | 1987-02-17 | 1988-12-16 | ファーミング ビーブイ | 効率的な分泌のための乳腺に出される蛋白におけるdna配列 |
EP0327378A1 (en) | 1988-02-05 | 1989-08-09 | The Trustees Of Columbia University In The City Of New York | Domain-modified constant region antibodies |
JPH02227075A (ja) | 1988-09-29 | 1990-09-10 | Kyowa Hakko Kogyo Co Ltd | 新規ポリペプチド |
JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
JP2517813B2 (ja) | 1990-05-29 | 1996-07-24 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | 生きている細胞に生物学的物質を導入するための改良された方法および装置 |
JPH04311385A (ja) | 1991-04-10 | 1992-11-04 | Kyowa Hakko Kogyo Co Ltd | ハイブリドーマの製造法 |
JPH05336963A (ja) | 1991-12-17 | 1993-12-21 | Kyowa Hakko Kogyo Co Ltd | 新規α2→3シアリルトランスフェラーゼ |
WO1994000977A1 (en) | 1992-07-07 | 1994-01-20 | Japan Tobacco Inc. | Method of transforming monocotyledon |
EP0598998A2 (en) | 1992-09-07 | 1994-06-01 | Kyowa Hakko Kogyo Co., Ltd | Humanized antibodies reacting with the ganglioside GM2 |
WO1994023021A1 (en) | 1993-03-29 | 1994-10-13 | Kyowa Hakko Kogyo Co., Ltd. | α-1,3-FUCOSYLTRANSFERASE |
WO1997010354A1 (en) | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR |
JPH10257893A (ja) | 1997-03-19 | 1998-09-29 | Kyowa Hakko Kogyo Co Ltd | ガングリオシドgm2に対するヒト型相補性決定領域(cdr)移植抗体 |
US20030158389A1 (en) | 1998-04-02 | 2003-08-21 | Genentech, Inc. | Polypeptide variants |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
US20050054832A1 (en) | 2002-03-01 | 2005-03-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
WO2003085107A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellules à génome modifié |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2007011041A1 (ja) * | 2005-07-22 | 2007-01-25 | Kyowa Hakko Kogyo Co., Ltd. | 遺伝子組換え抗体組成物 |
WO2010055993A1 (ko) | 2008-11-11 | 2010-05-20 | 시스템디엔디(주) | 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법 |
Non-Patent Citations (242)
Title |
---|
"A Laboratory Manual", 1992, W. H. FREEMAN AND COMPANY, article "Current Protocols in Molecular Biology; Baculovirus Expression Vectors" |
"A Laboratory Manual", 1992, W.H. FREEMAN AND COMPANY, article "Current Protocols in Molecular Biology; Baculovirus Expression Vectors" |
"Antibodies, A Laboratory manual", 1988, COLD SPRING HARBOR LABORATORY, article "Current Protocols in Molecular Biology" |
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
"Antibodies: A Laboratory Manual", 1998, COLD SPRING HARBOR LABORATORY |
"Antibody Engineering, A Practical Approach", 1996, IRL PRESS AT OXFORD UNIVERSITY PRESS |
"Biochemical Experimentation Methods 23 - Method for Studying Glycoprotein Sugar Chain", 1989, JAPAN SCIENTIFIC SOCIETIES PRESS |
"Biomanual Series 4 - Methods of Gene Transfer, Expression and Analysis", 1994, YODOSHA |
"Biomanual Series 8", 1995, YODOSHA, article "Gene Targeting, Preparation of Mutant Mice Using ES Cells" |
"cDNA Cloning", 1996, YODOSHA |
"Cell Technology", 1996, article "Experimental Protocol Series, Glycobiology Experimental Protocol, Glycoprotein, Glycolipid and Proteoglycan" |
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS |
"Current Protocols in Molecular Biology; A Laboratory Manual", 1989 |
"Developmental Engineering Experimentation Manual - Preparation of Transgenic Mice", 1987, KODANSHA |
"DNA Cloning 1: Core Techniques, A Practical Approach", 1995, OXFORD UNIVERSITY |
"Enzyme Antibody Technique", 1985, GAKUSAI KIKAKU |
"Enzyme Immunoassay", 1987, IGAKU SHOIN |
"Gene Targeting, A Practical Approach", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS |
"Manipulating the Mouse Embryo, A Laboratory Manual", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS, article "Gene Targeting, A Practical Approach" |
"Manipulating the Mouse Embryo, A Laboratory Manual", 1994, COLD SPRING HARBOR LABORATORY PRESS |
"Methods for Preparing Gene Libraries", 1994, YODOSHA |
"Molecular Cloning" |
"Molecular Cloning", 1987, article "Current Protocols in Molecular Biology" |
"Molecular Cloning", article "Current Protocols in Molecular Biology" |
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LAB. PRESS |
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
"Molecular Cloning, A Laboratory Manual", vol. 1-34, 1989, COLD SPRING HARBOR LAB. PRESS, article "Current Protocols in Molecular Biology" |
"Molecular Cloning, A Laboratory Manual", vol. 1-34, 1989, COLD SPRING HARBOR LABORATORY PRESS, article "Current Protocols in Molecular Biology" |
"Molecular Cloning, Second Edition, Current Protocols in Molecular Biology" |
"Monoclonal Antibodies: Principles and Applications", 1995, WILEY-LISS, INC. |
"Monoclonal Antibodies: principles and practice", 1993, ACAD. PRESS |
"Monoclonal Antibodies: Principles and Practice", 1996, ACADEMIC PRESS LIMITED |
"PCR Protocols", 1990, ACADEMIC PRESS |
"Seibutsukagaku Jikkenho", vol. 23, 1989, GAKKAI SHUPPAN CENTER, article "Totanpakushitsu Tosa Kenkyuho" |
"Sequence of Proteins of Immunological Interest", 1991 |
"Sequences of Proteins of Immunological Interest", 1991, US DEPT. HEALTH AND HUMAN SERVICES |
"Shin Seikagaku Jikken Koza", 1988 |
"Soshiki Baiyo no Gijutsu", 1996, ASAKURA SHOTEN |
AGRIC. BIOL. CHERN., vol. 55, no. 1, 1991, pages 283 - 284 |
AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 63, 1996, pages 627S |
AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 63, 1996, pages 639S |
ANAL. BIOCHEM., vol. 171, 1988, pages 73 |
ANALYTICAL BIOCHEMISTRY, vol. 162, 1987, pages 156 |
ANN. ALLERGY ASTHMA IMMUNOL., vol. 81, 1998, pages 105 |
BENTLEY K. J. ET AL., HYBRIDOMA, vol. 17, 1998, pages 559 - 567 |
BIO/TECHNOLOGY, vol. 17, 1999, pages 1097 |
BIO/TECHNOLOGY, vol. 2, 1991, pages 266 |
BIO/TECHNOLOGY, vol. 2, 1991, pages 830 |
BIO/TECHNOLOGY, vol. 6, 1988, pages 47 |
BIO/TECHNOLOGY, vol. 9, 1991, pages 266 |
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 149, 1987, pages 960 |
BIOCHEMISTRY, vol. 15, 1976, pages 5175 |
BIOCHEMISTRY, vol. 20, 1981, pages 2361 |
BIOSCIENCE AND INDUSTRY, vol. 50, 1992, pages 322 |
BIOTECHNOL. BIOENG., vol. 74, 2001, pages 288 |
BIOTECHNOL. BIOENG., vol. 87, 2004, pages 614 |
BIOTECHNOLOGY, vol. 2, 1992, pages 358 |
BLOOD, vol. 65, 1985, pages 1349 |
BLOOD, vol. 99, 2002, pages 754 |
BRADY G. ET AL., GENE, vol. 27, 1984, pages 223 - 232 |
BREKKE O.H. ET AL.: "Human IgG3 can adopt the disulfide bond pattern characteristic for IgG1 without resembling it in complement mediated cell lysis", MOL. IMMUNOL., vol. 30, no. 16, 1993, pages 1419 - 1425, XP023935453 * |
CANCER IMMUNOL IMMUNOTHER., vol. 36, 1993, pages 373 |
CANCER IMMUNOL. IMMUNOTHER., vol. 36, 1993, pages 373 |
CANCER IMMUNOL. IMMUNOTHER., vol. 37, 1993, pages 255 |
CANCER IMMUNOL. IMMUNOTHER., vol. 50, 2001, pages 275 |
CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 36, 1993, pages 373 |
CANCER RES., vol. 45, 1985, pages 2405 |
CANCER RES., vol. 45, 1985, pages 2642 |
CANCER RES., vol. 46, 1986, pages 4116 |
CANCER RES., vol. 46, 1986, pages 6489 |
CANCER RES., vol. 47, 1987, pages 1098 |
CANCER RES., vol. 47, 1987, pages 225 |
CANCER RES., vol. 48, 1988, pages 6154 |
CANCER RES., vol. 56, 1996, pages 1118 |
CANCER RES., vol. 64, 2004, pages 2127 |
CANCER RESEARCH, vol. 54, 1994, pages 1511 |
CELL TECHNOLOGY, vol. 12, 1993, pages 239 |
CELL TECHNOLOGY, vol. 12, 1997, pages 1463 |
CELL TECHNOLOGY, vol. 13, 1994, pages 255 |
CELL TECHNOLOGY, vol. 16, 1997, pages 1463 |
CELL, vol. 33, 1983, pages 717 |
CELL, vol. 41, 1985, pages 479 |
CELL, vol. 95, 1998, pages 1017 |
CHEMICAL IMMUNOLOGY, vol. 65, 1997, pages 88 |
CHEMISTRY, vol. 46, 1991, pages 681 |
CLIN. CANCER RES., vol. 10, 2004, pages 6248 |
CURR. OPIN. ONCOL., vol. 10, 1998, pages 548 |
CYTOTECHNOLOGY, vol. 1, 1990, pages 133 |
CYTOTECHNOLOGY, vol. 3, 1990, pages 133 |
CYTOTECHNOLOGY, vol. 4, 1990, pages 173 |
DNA CLONING, A PRACTICAL APPROACH, vol. 1, 1985, pages 49 |
DNA CLONING: A PRACTICAL APPROACH, vol. 1, 1985, pages 49 |
EUR. J IMMUNOL., vol. 21, 1991, pages 2379 |
EUR. J. IMMUNOL., vol. 29, 1999, pages 2819 |
EXPERIMENTAL MEDICINE, vol. 11, 1993, pages 2491 |
EXPERIMENTAL MEDICINE, vol. 9, 1991, pages 1937 |
FEBS LETT., vol. 328, 1993, pages 49 |
GENE THERAPY, vol. 5, 1999, pages 1960 |
GENE, vol. 200, 1997, pages 149 |
GENE, vol. 27, 1984, pages 223 |
GENE, vol. 33, 1985, pages 103 |
GENE, vol. 34, 1985, pages 315 |
GENE, vol. 38, 1985, pages 275 |
GENES DEVELOP., vol. 4, 1990, pages 1288 |
GENETICS, vol. 39, 1954, pages 440 |
GILLIES S. D. ET AL., CELL, vol. 33, 1983, pages 717 - 728 |
HEPATOLOGY, vol. 25, 1997, pages 1462 |
HUM ANTIB HYBRID, vol. 6, 1995, pages 82 |
HUM. MOL. GENET., vol. 5, 1995, pages 1083 |
HUMAN ANTIB HYBRID, vol. 5, 1994, pages 143 |
IMMUNOL. TODAY, vol. 20, 1999, pages 576 |
IMMUNOL. TODAY, vol. 21, 2000, pages 364 |
IMMUNOL. TODAY, vol. 21, 2000, pages 403 |
IMMUNOL., vol. 85, 1995, pages 668 |
IMMUNOLOGY, vol. 86, 1995, pages 319 |
INVEST. DERMATOL., vol. 11 L, 1998, pages 1172 |
J BACTERIOLOGY, vol. 153, 1983, pages 163 |
J BIOCHEM., vol. 101, 1987, pages 1307 |
J BIOL. CHEM., vol. 257, 1982, pages 12752 |
J BIOL. CHEM., vol. 264, 1989, pages 12122 |
J BIOL. CHEM., vol. 278, 2003, pages 3466 |
J CLIN. ONCOL., vol. 17, 1999, pages 2639 |
J CLIN. ONCOL., vol. 2, 1984, pages 881 |
J CLIN. ONCOL., vol. 21, 2003, pages 1466 |
J EXP. MED, vol. 155, 1982, pages 1133 |
J IMMUNOL. METHODS, vol. 167, 1994, pages 271 |
J LIQ. CHROMATOGR., vol. 2, 1983, pages 1577 |
J LIQ. CHROMATOGR., vol. 6, 1983, pages 1577 |
J MOL BIOL., vol. 16, 1966, pages 118 |
J MOL, BIOL., vol. 215, 1990, pages 403 |
J MOL. BIOL., vol. 112, 1977, pages 535 |
J MOL. BIOL., vol. 16, 1966, pages 118 |
J MOL. BIOL., vol. 166, 1983, pages 1 |
J MOL. MED., vol. 75, 1997, pages 829 |
J NATL. CANCER INST., vol. 80, 1988, pages 937 |
J. BIOCHEM., vol. 101, 1987, pages 1307 |
J. BIOCHEM., vol. 95, 1984, pages 197 |
J. BIOCHEMISTRY, vol. 101, 1987, pages 1307 |
J. BIOL. CHEM., vol. 277, 2002, pages 2673 |
J. CLIN. ONCOL., vol. 16, 1998, pages 2825 |
J. CLIN. ONCOL., vol. 17, 1999, pages 268 |
J. IMMUNOL., vol. 135, 1985, pages 1530 |
J. IMMUNOL., vol. 164, 2000, pages 4178 |
J. IMMUNOL., vol. 166, 2001, pages 2571 |
J. IMMUNOL., vol. 172, 2004, pages 3280 |
J. MOL. BIOL., vol. 166, 1983, pages 1 |
J. NATL. CANCER INST., vol. 80, 1988, pages 932 |
J. NUCL. MED, vol. 26, 1985, pages 1011 |
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 173, 1991, pages 1025 |
JOURNAL OFEXPERIMENTAL MEDICINE, vol. 166, 1987, pages 1351 |
KUWANA Y. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 149, 1987, pages 960 - 968 |
LANCET, vol. 1, 1989, pages 786 |
LOWE ET AL., PROC. NATL. ACAD SCI. USA, vol. 86, 1989, pages 8227 |
MASON J. O. ET AL., CELL, vol. 41, 1985, pages 479 - 487 |
METHODS ENZYMOL., vol. 194, 1990, pages 182 |
METHODS IN ENZYMOL., vol. 154, 1987, pages 3 |
METHODS IN ENZYMOLOGY, vol. 154, 1987, pages 3 |
METHODS IN ENZYMOLOGY, vol. 183, 1990, pages 63 |
MIYAJI H. ET AL., CYTOTECHNOLOGY, vol. 3, 1990, pages 133 - 140 |
MIYAJI H. ET AL., CYTOTECHNOLOGY, vol. 4, 1990, pages 173 - 180 |
MIZUKAMI T.; ITOH S., J BIOCHEM., vol. 101, 1987, pages 1307 - 1310 |
MOL. CELL. BIOL., vol. 3, 1983, pages 280 |
MOL. IMMUNOL., vol. 30, 1993, pages 1419 |
MOL. IMMUNOL., vol. 34, 1997, pages 1019 |
MOL. IMMUNOL., vol. 37, 2000, pages 995 |
MOL. LMMUNOL., vol. 37, 2000, pages 1035 |
NAT. BIOTECHNOL., vol. 17, 1999, pages 176 |
NATURE BIOTECH., vol. 16, 1998, pages 1343 |
NATURE BIOTECH., vol. 18, 2000, pages 43 |
NATURE BIOTECH., vol. 18, 2000, pages 555 |
NATURE BIOTECHNOL., vol. 16, 1998, pages 1015 |
NATURE CELL BIOL., vol. 2, 2000, pages 70 |
NATURE GENET., vol. 24, 2000, pages 314 |
NATURE GENET., vol. 25, 2000, pages 35 |
NATURE MEDICINE, vol. 4, 1998, pages 285 |
NATURE REVIEWS CANCER, vol. 1, 2001, pages 119 |
NATURE, vol. 195, 1962, pages 788 |
NATURE, vol. 227, 1970, pages 680 |
NATURE, vol. 312, 1984, pages 643 |
NATURE, vol. 321, 1986, pages 522 |
NATURE, vol. 329, 1987, pages 840 |
NATURE, vol. 332, 1988, pages 323 |
NATURE, vol. 391, 1998, pages 806 |
NATURE, vol. 395, 1998, pages 854 |
NUC. ACIDS RES., vol. 27, 1999, pages 1323 |
NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487 |
NUCLEIC ACIDS RESEARCH, vol. 13, 1985, pages 4431 |
NUCLEIC ACIDS RESEARCH, vol. 17, 1989, pages 9494 |
O'HARE K. ET AL., PROC. NATL. ACAD. SCI. USA., vol. 78, 1981, pages 1527 - 1531 |
ONCOGENE, vol. 22, 2003, pages 7359 |
PAULSON ET AL., J BIOL. CHEM., vol. 264, 1989, pages 17619 |
PROC. NATL. ACAD SCI. U.S.A., vol. 96, 1999, pages 1886 |
PROC. NATL. ACAD SCI. USA, vol. 79, 1982, pages 6409 |
PROC. NATL. ACAD SCI. USA, vol. 96, 1999, pages 1451 |
PROC. NATL. ACAD SCI. USA, vol. 96, 1999, pages 8774 |
PROC. NATL. ACAD SCI. USA., vol. 89, 1992, pages 4285 |
PROC. NATL. ACAD. SCI USA, vol. 82, 1985, pages 488 |
PROC. NATL. ACAD. SCI. (JSA, vol. 82, 1985, pages 488 |
PROC. NATL. ACAD. SCI. U.S.A, vol. 80, 1983, pages 5392 |
PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 1242 |
PROC. NATL. ACAD. SCI. US.A., vol. 78, 1981, pages 1527 |
PROC. NATL. ACAD. SCI. US.A., vol. 86, 1989, pages 4220 |
PROC. NATL. ACAD. SCI. USA, vol. 75, 1978, pages 1929 |
PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 |
PROC. NATL. ACAD. SCI. USA, vol. 84, 1978, pages 1929 |
PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 |
PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 13959 |
PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 15502 |
PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 5049 |
PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 8768 |
PROC. NATL. ACAD. SCI. USA., vol. 89, 1992, pages 4285 |
PROC. NATL. ACAD. SCI., USA, vol. 79, 1982, pages 6409 |
PROC. NATT. ACAD. SCI. USA, vol. 84, 1987, pages 7413 |
PROCEEDING OF THE SOCIETY FOR THE BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1 |
PROTEIN ENGINEERING, vol. 7, 1994, pages I501 |
PROTEIN, NUCLEIC ACID AND ENZYME, vol. 41, 1996, pages 603 |
SANGER ET AL., PROC. NATL ACAD. SCI. U.S.A., vol. 74, 1977, pages 5463 |
SANGER ET AL., PROC. NATL. ACAD SCI. U.S.A., vol. 74, 1977, pages 5463 |
SANGER ET AL., PROC. NATL. ACAD SCI., USA, vol. 74, 1977, pages 5463 |
SANGER ET AL., PROC. NATL. ACAD. SCI. US.A., vol. 74, 1977, pages 5463 |
SANGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 74, 1977, pages 5463 |
SCAND. J. IMMUNOL., vol. 32, 1990, pages 517 |
SCIENCE, vol. 122, 1952, pages 501 |
SCIENCE, vol. 222, 1983, pages 778 |
SCIENCE, vol. 273, 1996, pages 1386 |
SHITARA K., J IMMUNOL. METHODS, vol. 167, 1994, pages 271 - 278 |
SOMATIC CELL MOL, GENET., vol. 12, 1986, pages 555 |
SOMATIC CELL MOL. GENET., vol. 12, 1986, pages 51 |
SOSHIKI BAIYO, vol. 20, 1994 |
SOSHIKI BAIYO, vol. 21, 1995 |
STRATEGIES, vol. 5, 1992, pages 58 |
STRATEGIES, vol. 5, 1992, pages 81 |
STRUCTURE, vol. 8, 2000, pages 2 |
SUGANO ET AL., GENE, vol. 138, 1994, pages 171 |
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519 |
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 132 |
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 152 |
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 87 |
TRENDS IN BIOTECHNOLOGY, vol. 15, 1997, pages 45 |
VAN LOGHEM E. ET AL.: "Staphylococcal protein A and human IgG subclasses and allotypes", SCAND. J. IMMUNOL., vol. 15, no. 3, 1982, pages 275 - 278, XP008112756 * |
VIROLOGY, vol. 8, 1959, pages 396 |
YAMANE-OHNUKI N. ET AL.: "Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity", BIOTECHNOL. BIOENG., vol. 87, no. 5, 2004, pages 614 - 622, XP002983153 * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US11168344B2 (en) | 2005-03-31 | 2021-11-09 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US10934344B2 (en) | 2006-03-31 | 2021-03-02 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11332533B2 (en) | 2007-09-26 | 2022-05-17 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11359194B2 (en) | 2008-04-11 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9890377B2 (en) | 2008-04-11 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US10472623B2 (en) | 2008-04-11 | 2019-11-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US11371039B2 (en) | 2008-04-11 | 2022-06-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
WO2010018846A1 (ja) * | 2008-08-13 | 2010-02-18 | 協和発酵キリン株式会社 | ガングリオシドgm2に特異的に結合する抗体組成物を含む医薬 |
US10253091B2 (en) | 2009-03-19 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10066018B2 (en) | 2009-03-19 | 2018-09-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
WO2011078332A1 (ja) * | 2009-12-25 | 2011-06-30 | 中外製薬株式会社 | ポリペプチド多量体を精製するためのポリペプチドの改変方法 |
JP6087054B2 (ja) * | 2009-12-25 | 2017-03-01 | 中外製薬株式会社 | ポリペプチド多量体を精製するためのポリペプチドの改変方法 |
RU2606264C2 (ru) * | 2009-12-25 | 2017-01-10 | Чугаи Сеияку Кабушики Каиша | Способ полипептидной модификации для очистки полипептидных мультимеров |
JPWO2011078332A1 (ja) * | 2009-12-25 | 2013-05-09 | 中外製薬株式会社 | ポリペプチド多量体を精製するためのポリペプチドの改変方法 |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
US10450381B2 (en) | 2010-11-17 | 2019-10-22 | Chugai Seiyaku Kabushiki Kaisha | Methods of treatment that include the administration of bispecific antibodies |
US9334331B2 (en) | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US11066483B2 (en) | 2010-11-30 | 2021-07-20 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
WO2012073985A1 (ja) * | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
CN109160951A (zh) * | 2010-11-30 | 2019-01-08 | 中外制药株式会社 | 细胞毒诱导治疗剂 |
US11851476B2 (en) | 2011-10-31 | 2023-12-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11485790B2 (en) | 2014-04-07 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
US11505605B2 (en) | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
US11001643B2 (en) | 2014-09-26 | 2021-05-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008090960A1 (ja) | 2010-05-20 |
US20110236374A1 (en) | 2011-09-29 |
EP2107115A1 (en) | 2009-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008090960A1 (ja) | ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物 | |
EP1921090A4 (en) | GENETICALLY MODIFIED ANTIBODY COMPOSITION | |
WO2008090958A1 (ja) | ドメイン交換された遺伝子組換え抗体組成物 | |
WO2008090959A1 (ja) | エフェクター活性が増強された遺伝子組換え抗体組成物 | |
CN107921122B (zh) | 与cd38结合的抗体治疗剂 | |
EP3057994B1 (en) | Peptidic chimeric antigen receptor t cell switches and uses thereof | |
JP2021520192A (ja) | 癌に対する三重特異性結合分子及びその使用 | |
JP5214252B2 (ja) | ヒト化l243抗体 | |
CN116322788A (zh) | 环状rna组合物和方法 | |
JP2019513817A (ja) | Tigitに対する抗体 | |
EP3296320A1 (en) | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof | |
TW201726739A (zh) | Pd1/ctla4結合劑 | |
BRPI0717363B8 (pt) | imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina | |
CN111511764A (zh) | Clec9a结合剂及其用途 | |
RU2009147758A (ru) | Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей | |
CN105612175A (zh) | 基于IL-15和IL-15Rαsushi结构域的调节因子 | |
EP2581113A4 (en) | ANTI-TIM-3 ANTIBODIES | |
CA2849765A1 (en) | Hybrid constant regions | |
TWI500629B (zh) | 介白素-6抗體及其用途 | |
TWI639440B (zh) | 包括gm-csf中和化合物之液態配方 | |
EP3536711A1 (en) | Anti-cd26 antibodies and uses thereof | |
WO2009001840A1 (ja) | ADCC活性又はCDC活性を有する抗Prominin-1抗体 | |
EP3348569A1 (en) | Pan elr+ cxc chemokine antibodies | |
CN115894703A (zh) | 具有经修饰重链恒定区的多特异性重链抗体 | |
KR20230061391A (ko) | gp130 결합 분자 및 사용 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08703821 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2008555105 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12524215 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008703821 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |